

References

REFERENCES

- Abd El-Shahed, B. (2008):** Factors Affecting Quality of Life of Patients with Liver Cirrhosis. Unpublished Master's Thesis, In Nursing Science. Faculty of Ng, Ain Shames University, Egypt.
- Adeyi, O., Fischer, E., and Guindi, M. (2010):** Liver Allograft Pathology: Approach to Interpretation of Needle Biopsies with Clinicopathological Correlation. *J Clin Pathol. Jan*; 63 (1):47-74. [Medline].
- Ahmed, Belkacem, A., Ahnou, N., et al. (2010):** Silibinin and Related Compounds are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. *Gastroenterology. Mar*; 138 (3): 1112-22.
- Al Husiny, S. (2008):** Effect of Educational Program for Family Have A Member Infected with HCV, Faculty of Nursing, Mansoura University.
- AlAian, G., Wasley, A., Simard, E., et al. (2006):** The Prevalence of Hepatitis C Virus Infection in The United States, 1999 through 2002. *Annals of Internal Medicine.*; 144: 705–714.
- Alavian, S., Kabir, A., and Hajarizadeh, B. (2006):** Preliminary Report of Interferon Alfa 2b in Combination with Ribivirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: A quasi-Experimental Study. *Shiraz E-Medical Journal*, 7(1): 1-20.

Allen, A., Craxi , A., Kamal , S., et al. (2008): The Neglected Hepatitis C Virus Genotypes 4, 5 and 6: An International Consensus Report. *Liver Int Mar*; 30(3): 342-55.

Alter, M., Kruszon, Moran, D., Nainan, O., et al. (2000): The Prevalence of Hepatitis C Virus Infection in the United States. *N Engl J Med.*, 341(1): 556-62.

American Liver Foundation. "Cirrhosis" (Accessed 19 January 2011). Available at: <http://www.liverfoundation.org>.

Ascione, G., Alsiö, A., Pugnale, P., et al. (2010). "Systemic and Intrahepatic Interferon-Gamma-Inducible Protein 10 kDA Predicts The First-Phase Decline in Hepatitis C Virus RNA and Overall Viral Response to Therapy in Chronic Hepatitis C". *Hepatology*, 51 (5): 1523–30.

Awad, T., Thorlund, K., Hauser, G., et al. (2010): "Peginterferon Alpha-2a is Associated with Higher Sustained Virological Response than Peginterferon Alfa-2b in Chronic Hepatitis C: systematic review of randomized trials". *Hepatology*, 51 (4): 1176–84.

Bacon, B. (2011): "Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection". *N Engl J Med.* 364 (13): 1207–17.

Bacon, B., and Di Bisceglie, A. (2003): Liver Disease, (1st eds). New York: Churchill Livingstone. P.1079.

Bani-Sadr, F., Lapidus, N., Bedossa, P., et al. (2008): French National Agency for Research on AIDS; Viral Hepatitis-HC02-Ribavir Study Team. Progression of Fibrosis in HIV and Hepatitis C Virus-Coinfected Patients Treated with Interferon Plus Ribavirin-Based

Therapy: Analysis of Risk Factors. *Clin Infect Dis.* Mar 1; 46 (5): 768-74.

Berg, T., Mc Hutchison, J., Adda, N., et al. (2010): SVR with Telaprevir, Peginterferon-Alfa2a and Ribavirin in HCV Patients with Well-Characterized prior Null Response, Partial Response, Viral Breakthrough or Relapse after PR: Rollover Study 107. 45th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria. 14-18 April.

Bertaux, C., and Dragic, T. (2006) Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry. *J Virol.* 80: 4940–4948.

Biermer, M., Berg, T., (2009): Rapid Suppression of Hepatitis C Viremia Induced by Intravenous Silibinin plus Ribavirin. *Gastroenterology.*

Black, J., and Hawks, J. (2009): Medical Surgical Nursing Clinical Management for Positive Outcomes, 8th ed., Saunders Elsevier Enc., U.S.A., Pp; 1147-1177

Blanchard, E., Belouzard, S., Goueslain, L., et al. (2006): Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis. *J Virol* 80: 6964–6972.

Butt, A., McGinnis, K., Skanderson, M., Justice, A., (2010): Hepatitis C Treatment Completion Rates in Routine Clinical Care, *Liver Int.*

Cachafeiro, S., Lewden, C., Hernando, V., et al. (2010): CoRIS/CoRIS-MD All-Cause Mortality in HIV-Infected Patients in Spain Compared to the General Population according

to HCV Status. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco.

Canobbio, M., and Mosby, H. (2001): Booh of patients' teaching. 2nd Ed. Louis Harcourt Health Science Company. 270-3, 306-10.

Cardoso, A., Moucari, R., Figueiredo-Mendes, C., et al. (2010): Impact of Peginterferon and Ribavirin Therapy on Hepatocellular Carcinoma: Incidence and Survival in Hepatitis C Patients with Advanced Fibrosis. *J Hepatol.* 52 (5): 652-7.

Caruntu, F., and Benea, L. (2006): "Acute Hepatitis C Virus Infection: Diagnosis, Pathogenesis, Treatment". *Journal of Gastrointestinal and Liver Diseases*, 15 (3): 249–56. PMID 17013450. http://www.jgld.ro/32006/32006_7.html accessed on 1.5.2011.

Chang, S., Jiang, J., Cai, Z., et al. (2007) :Human Apolipoprotein E is Required for Infectivity and Production of Hepatitis C Virus in Cell Culture. *J Virol*; 81: 13783–13793.

Cheng , G. & Wieland, S. (2008): Cellular Determinants of epatitis C Virus Assembly, Maturation, Degradation, and Secretion. *J Virol*; 82: 2120-29.

Ciczora, Y., Callens, N., and Penin, F., et al. (2007): Transmembrane Domains of Hepatitis C Virus Envelope Glycoproteins: Residues Involved in E1E2 Heterodimerization and Involvement of These Domains in Virus Entry. *J Virol* 81: 2372–2381.

Cotran, Ramzi, S., Kumar, et al. (2005): Robbins and Cotran Pathologic Basis of Disease (7th ed.). St. Louis, MO: Elsevier Saunders. p. 878.

Darling, J., Aerssens, J., Fanning, G., et al. (2010): Quantitation of pre-Treatment Serum IP-10 Improves the Predictive Value of an IL28B Gene Polymorphism for Hepatitis C Treatment Response. 61ST Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 29 October –2 November, 2010.

Das-Douglas, M., et al. (2010): 'Decreases in Community Viral Load are Associated with A Reduction in New HIV Diagnoses in San Francisco', Session 10-Oral, Paper 33, 17th Conference on Retroviruses and Opportunistic Infections.

Donlin, M., Cannon, N., Aurora, R., et al. (2010): Virahep-C Study Group. Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American patients. PLoS One. Feb 3; 5(2): e 9032

Donnell, D. (2010): 'Heterosexual HIV-1 Transmission after Initiation of Antiretroviral Therapy: A prospective Cohort Analysis', The Lancet, DOI: 10.1016/S0140-6736 (10) 60705.

Dreux, M., Boson, B., Ricard-Blum, S., et al. (2007): The Exchangeable Apolipoprotein APOC-I Promotes Membrane Fusion of Hepatitis C Virus. *J Biol Chem.* 282: 32357–32369.

Dubuisson, J. (2007): "Hepatitis C Virus Proteins". *World J. Gastroenterol.* 13 (17): 2406–15. PMID 17552023.

Egypt Demographic and Health Survey, (2008): Egyptian: Ministry of Health. El-Zanaty and Associates, and Macro International. Cairo. p 431.

Egypt Demographic Health Survey (2009): Final Report, This study Completed the First Representative National Sample of HCV

Antibody and HCV RNA. The Final Estimated Prevalence of HCV Antibody was 14.7%. / El-Zanaty F, Way A.

El-Shikh, A. (2003): The Impact of A Protocol of Care on Physical Responses and Compliance Among Patients with Congestive Heart Failure. Unpublished Doctoral degree. Faculty of Nursing; Menoufyia university.

El-Zanaty F. and Way A. Egypt Demographic and Health Survey, (2009): Egyptian: Ministry of Health. El-Zanaty and Associates, and Macro International. Cairo. p 431.

Embry and Jason. (2007): High Rates of Early Viral Response, Promising Safety Profile and Lack of Resistance-Related Breakthrough in HCV GT 1/4 Patients Treated with RG7128 Plus Peg IFN Alfa-2a (40KD)/RBV: Planned Week 12 Interim Analyses From.

Falkowska, E., Kajumo, F., Garcia, E., et al. (2007): Hepatitis C Virus Envelope Lycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization. *J Virol*; 81: 8072–8079.

Fareed, (2009): "The role of Parenteral Antischistosomal Therapy in The Spread of Hepatitis C Virus in Egypt". *Lancet*; 355 (9207): 887–91.

Fareed, (2009): Dietary Management in Chronic Renal Failure Patients and Its Effects on Nutritional States, Renal Function Tests and Serum Electrolytes. Unpublished Doctoral degree, Faculty of Nursing; Menoufyia University.

Fareed, M. (2004): Dietary management in chronic renal failure patients and its effects on nutritional states, renal function tests and

serum electrolytes. Unpublished Doctoral degree, Faculty of Nursing; Menoufyia University. مكرر

Flemming, J., Hurlbut, J., Mussari, B., et al. (2009): Liver Biopsies for Chronic Hepatitis C: Should Nonultrasound-Guided Biopsies be Abandoned?. *Can J Gastroenterol.* Jun; 23(6):425-30.

Forns, X., Marcellin, P., Ferenci, P., et al. (2009): On-Treatment Response-Guided Therapy with Telaprevir q8h or q12h Combined with Peginterferon Alfa-2a or Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C (study C208). [abstract 56]. 44th Annual Meeting.

Garieb, H. (2008): QOL and Associated Factors in Patient with C Viral Liver Disease. Unpublished Master's Thesis, In Nursing Science. Faculty of Ng, Ain Shames University, Egypt.

Gastaminza, P., Cheng, G., Wieland, S., et al. (2008): Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion. *J Virol*; 82: 2120-29.

Ghalib, R. (2005): Assessment of The Patients who Failed Treatment Forchronic Hepatitis C. *Gastroentrology Nursing*, 28 (suppl.1): 24-30.

Gordon, F., Brown, R., Kwo, P., et al. (2007): Peginterferon Alfa-2b and Ribavirin for Hepatitis C Recurrence Post-Orthotopic Liver Transplantation (OLT): Final results from the Protect.

Grove, J., Huby, T., Stamataki, Z., et al. (2007): Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity. *J Virol*; 81: 3162–3169.

Hellard, M., Sacks-Davis, R., Gold, J. (2009): Hepatitis C Treatment for Injection Drug Users: A Review of The Available Evidence. *Clin Infect Dis.* Aug 15; 49(4): 561-7.

Helle, F., Goffard, A., Morel, V., et al. (2007): The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies is Modulated by Specific Glycans on The E2 Envelope Protein. *J Virol*; 81: 8101–8111.

Heneedy, W. (2009): Study of The Effect of Nursing Intervention on Physical Responses and Compliance among Patients with Liver Cirrhosis at National Liver Institute and Menoufyia university hospital. Unpublished Doctoral Thesis.

The National Institute of Drug Abuse (NIDA), (2011): What the Science Says. NCCAM March (Retrieved 07 March 2011).Hepatitis C Infection,

Hepatitis Central News, (2010): Hepatitis-central.com. <http://www.hepatitis-central.com/mt/archives,accessed on7.8.2010heterosexual mo.html>. Retrieved 2010-08-27.

Health Information for International Travel, (2008): Association for the Study of the Liver. Copenhagen, Denmark. 22-26 April, 2009. SPRINT-2. [abstract LB-15] 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 29.

Honolulu and Doha, (2010): The Arab Republic of Egypt has the Highest Rates of New Hepatitis C Virus (HCV) Infection in the world, According to A new Study Published Today in The Prestigious.

- Houghton, M. (2009):** "The Long and Winding Road Leading to The Identification of The Hepatitis C Virus". *Journal of Hepatology*; 51 (5): 939–48.
- Huang, H., Sun, F., Owen, D., et al. (2007):** Hepatitis C Virus Production by Human Hepatocytes Dependent on Assembly and Secretion of Very Low-Density Lipoproteins. *Proc Natl Acad Sci USA*. 104: 5848–5853.
- Jacobson, I., McHutchison, J., Dusheiko, G., et al. (2010):** Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naive Patients: Final Results of Phase 3 Advance Study. *Hepatology*; 52: S427.
- Jensen, D., Wedemeyer, H., Herring, R., J., et al. (2010):** High Rates of Early Viral Response, Promising Safety Profile and Lack of Resistance-Related Breakthrough in HCV GT 1/4 Patients Treated with RG7128 Plus Peg IFN Alfa-2a (40KD)/RBV: Planned week 12 interim analyses from.
- Juall, L., and Moyet, C., (2009):** Nursing Care Plans & Documentation Textbook. Nursing Diagnoses and Collaborative Problems. Wolters Kluwer Health/ Lippincott Williams & Wilkins Co. China. 5th Edition; PP: 98- 106.
- June, M., Gortrude, K., Jane, E., et al. (1997):** Mosby's Clinical Nursing, (4th ed.) London: Mosby, pp.769, 770.
- Kamal, S. (2008):** "Acute Hepatitis C: A Systematic Review". *The American Journal of Gastroenterology*; 103 (5): 1283–97; quiz 1298.

- Kohaar, I., Ploss, A., Korol, E., et al. (2010):** "Splicing Diversity of The Human OCLN Gene and Its Biological Significance for Hepatitis C Virus Entry". *Journal of Virology*; 84 (14): 6987-94.
- Lagging, M., Askarieh, G., Negro, F., et al. (2010):** "Response Prediction in Chronic Hepatitis C by Assessment of Baseline Levels of IP-10 and IL28B-Related Single Nucleotide Polymorphisms". *PLoS One*; 6 (2): e17232.
- Lavie, M., Goffard, A., and Dubuisson, J. (2007):** Assembly of A Functional HCV Glycoprotein Heterodimer. *Curr Issues Mol Biol*; 9: 71–86.
- Lawiz E, Rodriguez-Torres M, Rustgi, V., et al. (2010):** Safety and Efficacy of ANA 598 in Combination with Pegylated Interferon α 2A Plus Ribavirin in Treatment Naïve Genotype-1 Chronic HCV Patients. [abstract 31] 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 29 October – 2 November.
- Leasia, A., Marilyn, C., and Shelley, M., (2004):** A practical Guide to Health Assessment Frances Donovan Monahan, (2nd ed.). 25B. no.7, pp 216,89.
- Lettmeier, B., Mühlberger, N., Schwarzer, R., et al. (2008):** Market Uptake of New Antiviral Drugs for The Treatment of Hepatitis C. *J Hepatol*; Oct; 49 (4): 528-36.
- Linton, D. (2007):** Introduction to Medical Surgical Nursing. (4th ed.) Sunders Elsevier, Philadelphia, USA, Pp.808-814.
- Maieron, A., Metz-Gercek, S., Hackl, F., et al. (2010):** Chronic Hepatitis C In Austria, 1992-2006: Genotype Distribution and Demographic Factors. *Euro Surveill*. Feb 25; 15(8): 19492.

- Manns, M., Muir, A., Adda, N., et al. (2009):** Telaprevir in Hepatitis C Genotype 1-Infected Patients with Prior Non-Response, Viral Breakthrough, or Relapse to Peginterferon-Alpha 2a/b and Ribavirin Therapy: SVR results of the PROVE 3 study. [abstract 1044] 44th Annual Meeting.
- Marcellin, P., Forns, X., Goeser, T., et al (2009):** Virological Analysis of Patients Receiving Telaprevir Administered q8h or q12h with Peginterferon-Alfa- 2a or Alfa-2b and Ribavirin in Treatment-Naïve Patients with Genotype 1 Hepatitis C: study C208. [abstract 194] 60th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 30 October -1 November.
- Martn-Santos, R., Dez-Quevedo, C., Castellv, P., et al. (2009):** De novo Depression and Anxiety Disorders and Influence on Adherence During Peginterferon-Alpha-2a and Ribavirin Treatment in Patients with Hepatitis C. *Aliment Pharmacol Ther.* Feb 1; 27(3): 257-65.
- Marwan, E., Algendy M., Serag E., et al. (2008):** Liver Diseases. Treatment and Prevention. 2ND ed. National Liver Institute..
- Maynard, M., Pradat, P., Bailly, F., et al. (2006):** "Amantadine Triple Therapy for Non-Responder Hepatitis C Patients. Clues for controversies (ANRS HC 03 BITRI)". *Journal of Hepatology*; 44 (3): 484.
- McCown, M., Rajyaguru, S., Kular, S., et al. (2010):** GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796. *Antimicrob Agents Chemother*; 53: 2129-32.

McDonald, S., Hutchinson, S., Mills, P., et al. (2010): Diagnosis of Hepatitis C Virus Infection in Scotland's Injecting Drug User Population. *Infection and Epidemiology*, 138. pp. 393-402.

McHutchison, J., Goodman, Z., Patel, K., et al. (2010): Farglitazar Study Investigators. Farglitazar Lacks Antifibrotic Activity in Patients with Chronic Hepatitis C Infection. *Gastroenterology*. Apr; 138(4): 1365-73, 1373.

Medrano, J., Resino, S., Vispo, E., et al. (2010): Hepatitis C Virus (HCV) Treatment Uptake and Changes in The Prevalence of HCV Genotypes in HIV/ HCV-Coinfected Patients. *J Viral Hepat.* Apr 27.

Meier ,V., and Ramadori, G. (2009): "Hepatitis C Virus Virology and New Treatment Targets". *Expert Rev Anti Infect Ther.* 7 (3): 329–50. Retrieved 2011-04-16.

Miller, (2001): Phase 1b Study of Pegylated Interferon Lambda 1 with or without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection. *Hepatology*; 52: 822-32.

Mills, P., Bird, S., Robertson, C., et al. (2010): Diagnosis of Hepatitis C Virus Infection in Scotland's Injecting Drug User Population. *Infection and Epidemiology*, 138. pp. 393-402.

Mohamed, M. (2011): Hepatitis C Virus (HCV) Infection in a Community in The Nile Delta: Population Description and HCV Prevalence. *Hepatology*, 32: 111-15.

Mohamed, N., H. (2001): Rehabilitation Program to Improve Quality of Life for Patients Undergoing Renal Dialysis. Thesis for the Degree of Doctorate, Community and Environmental Health Nursing, Faculty of Nursing, Ain Shams University, P.95.

- Mohsen, A. (2009):** Effect of Nursing Management Protocol in Selected Side Effect of Combination Therapy, Faculty of Medicine, Menofia University, Egypt.
- Molina, S., Castet, V., Pichard-Garcia, L., et al. (2008):** Serum Derived HCV Infection of Primary Human Hepatocytes is Tetraspanin CD81 Dependent. *J Virol*; 82: 569–574.
- Morgan, T., Ghany, M., Kim, H., et al. (2010):** HALT-C Trial Group. Outcome of Sustained Virological Responders with Histologically Advanced Chronic Hepatitis C. *Hepatology*. Sep; 52(3): 833-44.
- Muir, A., Shiffman, M., Zaman, A., et al. (2010):** Phase 1b Study of Pegylated Interferon Lambda 1 with or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection. *Hepatology*; 52: 822-32.
- National Liver Institute, (2003):** Community Services Division. available at: <http://www.liver eg.org/postgraduate links.htm>.
- Neumann, U., Biermer, M., Eurich, D., et al. (2010):** Successful Pevention of Hepatitis C Virus (HCV) Liver Graft Reinfection by Silibinin Mono-Therapy. *J Hepatol*. Jun; 52(6): 951-2.
- NIH Consensus Development Conference on Management of Hepatitis C, (2002):** available at: http://consensus.nih.gov/2002/2002_HepatitisC2002116main.htm. Retrieved 22 February,accessed on 1.7.2011.
- Peters, L. (2010):** Insight SMART Study Group. Biomarkers of Inflammation and Coagulation and Risk of Non-AIDS Death in HIV/Hepatitis Co-infected Patients in the SMART Study. 17th

Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 16-19 February.

Phipps, W., Monaha, F., Sands, J., et al. (2007): Medical-Surgical Nursing Health and Illness Perspectives, Europe, Middle East and Africa, (8th ed.) Europe, Mosby, pp. 1316-1331.

Picchio, G., Luo, D., George, S., et al. (2010): Discrepancies between Definitions of Null Response to Treatment with Peginterferon Alfa-2A and Ribavirin: Implications for New HCV Drug Development [abstract 289] 45th Annual Meeting of the European Association for the Study of the Liver. 14- 18 April. Vienna, Austria.

Pinelo, E., and Presa, J. (2009): Outpatient Percutaneous Liver Biopsy: Still A good Option. *Eur J Intern Med.* Sep; 20(5): 487-89.

Pollack, A. (2011): 'Merck's Hepatitis C Drug Wins F.D.A Approval' The New York Times PMID 19034238. <http://www.medigraphic.com/pdfs/hepato/ah-2008/ah084j.pdf>. Accessed on 14.9.2011. "More Recently, Thymalfasin (Thymosin Alpha 1, Tα1, ZADAXIN, SciClone Pharmaceuticals, Inc., CA, USA) has Shown Efficacy in The Treatment of Chronic HCV Infection.

Poo, J., Sánchez, Avila, F., et al. (2008): "Efficacy of Triple Therapy with Thymalfasin, Peginterferon α-2a, and Ribavirin for The Treatment of Hispanic Chronic HCV Nonresponders" *Ann Hepatol*; 7 (4): 369–75.

Poordad, F. (2011): "Boceprevir for Untreated Chronic HCV Genotype 1 Infection". *N Engl J Med.* 364 (13): 1195–206. doi: 10.1056/NEJMoa1010494. PMID 21449783.

- Ragni, M., Moore, C., Soadwa, K., et al. (2011):** The HHH Study Group. Impact of HIV on Liver Fibrosis in Men with Hepatitis C Infection and Haemophilia. *Haemophilia*. 17(1): 103-11.
- Rallon, N., Naggie, S., Benito, J., et al. (2010):** Strong Association of a Single Nucleotide Polymorphism Located Near the Interleukin-28b Gene with response to Hepatitis C Therapy in HIV/HCV Co-infected Patients. [abstract 165 LB] 17th Conference on Retroviruses and Opportunistic.
- Ramadan, R. (2006):** Factors Affecting Self- Care for Patient with Leukemia. Thesis of the Master Degree Medical Surgical Nursing, Ain Shams University, pp.58, 52.
- Reau, N., Hadziyannis, S., Messinger, D., et al. (2008):** Early Predictors of Anemia in Patients with Hepatitis C Genotype 1 Treated with Peginterferon Alfa-2a (40KD) Plus Ribavirin. *Am J Gastroenterol*. Aug; 103 (8): 1981-8.64.
- Rochsroh, (2011):** A Counterargument is Provided by Power C Whither Prometheus' Liver? Greek Myth and the Science of Regeneration. *Annals of Internal Medicine*; 149 (6): 421-426.
- Rockstroh, J. (2009):** Hot Topics in HIV and Hepatitis Co-infection: Noninvasive Diagnosis of Liver Disease, Liver Transplantation, and New Drugs for Treatment of Hepatitis Coinfection. *HIV Clin Trials*; 10: 110-5.
- Rodriguez, Torres, M., Jeffers, L., et al. (2009):** Latino Study Group. Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C. *N Engl J Med*. Jan 15; 360 (3): 257-67.
- Rodriguez-Torres, M., Slim, J., Bhatti, L., et al. (2009):** Standard Versus High Dose Ribavirin in Combination with Peginterferon

Alfa-2a (40KD) in Genotype 1 (G1) HCV Patients Coinfected with HIV: Final results of the PARADIGM study. P. 1561.

Romano, K., Ali, A., and Schiffer, C. (2010): Avoiding Drug Resistance Against HCV NS3/4A Protease Inhibitors. *Antiviral Therapy*; 15 Suppl 2: A1-A189.

Rosdable, C. (1999): Text Book of Basic Nursing, (7th ed). New York: Lippincott, Pp.1279, 1280.

Rossignol, J., Elfert, A., El-Gohary, Y., et al. (2009): Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated with Nitazoxanide, Peginterferon, and Ribavirin. *Gastroenterol*; 136: 856-62.

Rumi, M., Aghemo, A., Prati, G., et al. (2010): Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. *Gastroenterology*.; 138: 108–115.

Saadoun, D., Resche-Rigon,M., Sene, D., et al. (2010): Resistance to direct antiviral agents in patients with hepatitis C virus infection. *Gastroenterol*; 138: 447-62.

Sabry M., and Abbas, (2009): Consensus proposals for a unified system
Department of Community Health Nursing1, Adult Health
Department , Faculty of medicine, Menofia University, Egypt

Saleh, D. (2008): Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. *Transactions of the Royal Society of Tropical Medicine and Hygiene*.

Sarrazin, C., Berg, T., Ross,R., et al. (2010): Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German

Guidelines on The Management of HCV Infection. *Gastroenterol*; 48: 289-351.

Satapathy, S., Lingisetty, C., Proper, S., et al. (2010): Equally Poor Outcomes to Pegylated Interferon-Based Therapy in African Americans and Hispanics with Chronic Hepatitis C Infection. *J Clin Gastroenterol*. Feb; 44(2): 140-5.

Schifer, M., and Mauss, S. (2008): Clinical Management of Interferon-Alpha-Associated Psychiatric Side Effects During Hepatitis C Treatment in Patients with Drug Addiction. *Cur Drug Abuse Rev*; 1: 177-87.

Schiff, E., Poordad ,E., Jacobson, I., et al. (2008): Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness. *J Hepatol*; 48: S46-S46.

Schwarzer, R and Schrder, K. (2004): Effects of self efficacy and social support on post surgical recovery of heart patients. *Irish Journal of Psychology* , 18(1): 88-103.

Schwarzinger, M., Dewedar, S., Rekacewicz, C., Abd Elaziz, K., M., et al. (2004): Quality of Life and everyday Activities in Patients with Primary Biliary Cirrhosis *Hepatology, J*, 46(6): 1836: 1843.

Seyam M., Freshwater, D., O'Donnell, K., and Mutimer, D. (2005): Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C. *Journal of Viral Hepatitis* 12(5):531-535. (9),

Simmonds, P., Bukh, J., Combet, C., Deléage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspé, G., Kuiken, C., Maertens, G., Mizokami ,M., Murphy, D., Okamoto, H., Pawlotsky, J., Penin, F., Sablon, E., Shin, I., T., Stuyver, L.,

- Thiel, H., Viazov, S., Weiner, A., Widell, A. (2005):** "Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes". *Hepatology* 42 (4): 962.
- Singal, A., Volk, M., Jensen, D., D., Bisceglie, A., Schoenfeld, P. (2010):** A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. *Clin Gastroenterol Hepatol*. Mar; 8(3): 280-8, 288.e1
- Smeltzer, S., C., Bare, B., G., (2004):** Bruner and Saddarth's text Book of Medical Surgical Nursing, 10th ed., Lippincott Williams Philadelphia Co., U.S.A., Pp; 1075,1101-1113
- Soadwa, (2011):** Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C". *Hepatology* 51 (5): 1523–30.
- Sorrentino, S., A., and Gorek, B., (2003):** Mosby's Text- book for Long- Term Care Assistants, (4th ed) USA: Mosby, p.466.
- Sterling, R, Bralow, S. (2006):** Extrahepatic manifestations of hepatitis C virus. *Curr Gastroenterol Rep*. Feb 2006;8(1):53-9.
- Susser, S., Welsch, C., Wang, Y., et al. (2009):** Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. *Hepatol*; 50: 1709-18.
- The Textbook of Hepatology,(2007):** From Basic Science to Clinical Practice by Juan Rodes (Editor), Mario Rizzetto (Editor), Jean-Pierre Benhamou (Editor), Andres Blei (Editor), Juerg Reichen (Editor) Pub. Date: August 2007.

- Thein, H., Y., Q., Dore, G., Krahn ,M. (2008):** Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. *AIDS*. 2008 Oct 1; 22(15): 1979-91.
- Thio, C., Martin, M., et al. (2009):** "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". *Nature* 461 (7265): 798–801. doi: 10.1038/nature08463. PMID 19759533.
- Thomas, D., Thio, C., Martin, M., et al. (2009):** "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". *Nature* 461 (7265): 798–801. doi: 10.1038/nature08463. PMID 19759533.
- Three-dimensional Anatomy of the Couinaud Liver Segments, (2009)**
<http://dpi.radiology.uiowa.edu/nlm/app/livertoc/liver/liver.html>.
accessed on 7.9.2011.
- Thuluvath, P., Guidinger, M., Fung, J., Johnson, L., Rayhill, S., Pelletier ,S.(2010):** Liver transplantation in the United States, 1999-2008. *Am J Transplant*. 2010 Apr; 10(4 Pt 2): 1003-19
- Timby and Smith, (2010):** Introduction to Medical Surgical Nursing. 10Th ed, Lippincott Williams, Philadelphia, London, Pp.704- 717.
- Tohme, R., Holmberg, S., (2010):** "Is sexual contact a major mode of hepatitis C virus transmission?". *Hepatology* 52 (4): n/a. CDC (2010, July) 'HIV in the United States'
- Torriani, F., et al. (2004):** Peginterferon Alfa-2a plus ribavirin for chronic. Treatment duration and ribavirin dose *Ann Intern Med* 2004, 140:

- Tuaillon, E., Mondain, A., Meroueh, F., et al. (2010):** Dried blood spot for hepatitis C virus serology and molecular testing. *Hepatology*.
- Tuke, P., Grant ,P., Waite ,J., Kitchen ,D., Eglin ,R., Tedder ,R. (2008):** Hepatitis C virus window-phase infections: closing the window on hepatitis C virus. *Transfusion*. Apr; 48(4): 594-600.
- Verma, S., Bonacini ,M., Govindarajan ,S., Kanel ,G., Lindsay ,K., Redeker ,A.(2006):** More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. *Am J Gastroenterol*. 2006 Aug; 101(8): 1817-23. Verbeeck J, Stanley MJ, Shieh J, et al. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. *J Clin Microbiol*. 2008 Jun; 46(6): 1901-6.
- Vescio, M., Longo ,B., Babudieri ,S., et al. (2008):** "Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis". *Journal of Epidemiology and Community Health* 62 (4): 305–13.
- Vogel, M., Rockstroh, J. (2010):** Treatment of acute hepatitis C in HIV infection. *J Antimicrob Chemother*. 2010 Jan; 65(1): 4-9.
- Voisset, C., Lavie, M., Helle, F., Op De Beeck, A., Bilheu, A., Bertrand-Michel, J., et al. (2007):** Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. *Cell Microbiol* (epub ahead of print).
- Volk, M., Tocco, R., Saini, S., Lok, A. (2007):** Public health impact of antiviral therapy for hepatitis C in the United States. *Hepatology*.

Welsch, C., Domingues, F., Susser, S., et al. (2008): Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. *Genome Biol*; 9: R16.

WHO, (2009): 30th November) 'Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents'.

Winters, M., Chary, A., Eison, R., Asmuth, D., Holodniy, M. (2010): Impact of highly active antiretroviral therapy on hepatitis C virus protease quasidiversispecieity in HIV co-infected patients. *J Med Virol*. May; 82(5): 791-8.

World Health Organization. Initiative for Vaccine Research (IVR). (2009): Viral Cancers, Hepatitis C. 2009. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html .Accessed 3.4.2011. Faculty of Nursing; Menoufyia University.

World Hepatitis Alliance. (2011): Viral Hepatitis: Global Policy. Available at: <http://www.worldhepatitisalliance.org/Policy/2010PolicyReport.aspx> ,accessed on 22.7.2011.

Younossi, Z., Nader, F., Bai ,C., et al. (2008): A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. *J Viral Hepat* 15: 370-78.

Zeuzem, S., Buggisch, P., Agarwal, K., et al. (2010): Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or pegIFN/RBV for up to 28 days in treatment naive , genotype 1 HCV subjects. *Hepatol a*; 50: S106.

- Zheng, A., Yuan, F., Li, Y., Zhu, F., Hou, P., Li, J., et al. (2007):** Claudin-6 and Claudin-9 function as additional co-receptors for hepatitis C virus. *J Virol* 81: 12465–12471.
- Zucker, D., and Miller, B. (2001):** Assessment of side effects in patients with chronic hepatitis C receiving combination therapy. *Gastroenterology Nursing*, 24(4):192-196. (8)